HK1255379A1 - 丙型肝炎病毒免疫原性組合物及其使用方法 - Google Patents

丙型肝炎病毒免疫原性組合物及其使用方法

Info

Publication number
HK1255379A1
HK1255379A1 HK18114518.4A HK18114518A HK1255379A1 HK 1255379 A1 HK1255379 A1 HK 1255379A1 HK 18114518 A HK18114518 A HK 18114518A HK 1255379 A1 HK1255379 A1 HK 1255379A1
Authority
HK
Hong Kong
Prior art keywords
hepatitis
methods
immunogenic compositions
virus immunogenic
virus
Prior art date
Application number
HK18114518.4A
Other languages
English (en)
Inventor
Michael Houghton
John L Law
Michael Logan
Darren Hockman
Abdolamir Landi
Original Assignee
Univ Alberta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Alberta filed Critical Univ Alberta
Publication of HK1255379A1 publication Critical patent/HK1255379A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK18114518.4A 2015-07-07 2018-11-14 丙型肝炎病毒免疫原性組合物及其使用方法 HK1255379A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562189657P 2015-07-07 2015-07-07
PCT/IB2016/001051 WO2017006182A1 (en) 2015-07-07 2016-07-06 Hepatitis c virus immunogenic compositions and methods of use thereof

Publications (1)

Publication Number Publication Date
HK1255379A1 true HK1255379A1 (zh) 2019-08-16

Family

ID=57686164

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18114518.4A HK1255379A1 (zh) 2015-07-07 2018-11-14 丙型肝炎病毒免疫原性組合物及其使用方法

Country Status (5)

Country Link
US (4) US10300131B2 (zh)
EP (1) EP3319997A4 (zh)
CA (1) CA2986342C (zh)
HK (1) HK1255379A1 (zh)
WO (1) WO2017006182A1 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016336150B2 (en) * 2015-10-08 2023-08-10 The Governors Of The University Of Alberta Hepatitis C virus E1/E2 heterodimers and methods of producing same
AU2017332854A1 (en) 2016-09-21 2019-04-11 The Governors Of The University Of Alberta Hepatitis C virus immunogenic compositions and methods of use thereof
JP7464954B2 (ja) * 2017-04-27 2024-04-10 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Ｃ型肝炎ウイルスに対するヌクレオシド修飾ｍＲＮＡ－脂質ナノ粒子系統ワクチン
CA3093314A1 (en) * 2018-03-16 2019-09-19 The Governors Of The University Of Alberta Hepatitis c virus peptide compositions and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004301A2 (en) 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same
WO1998050556A2 (en) 1997-05-06 1998-11-12 Chiron Corporation Intracellular production of hepatitis c e1 and e2 truncated polypeptides
CA2636032C (en) * 2006-01-04 2016-04-12 Novartis Vaccines And Diagnostics, Inc. Activation of hcv-specific t cells
JP5474547B2 (ja) 2006-08-25 2014-04-16 ノバルティス アーゲー Ｈｃｖ融合ポリペプチド
WO2014060851A2 (en) * 2012-10-05 2014-04-24 The Governors Of The University Of Alberta Hepatitis c virus immunogenic compositions and methods of use thereof
CU24112B1 (es) * 2012-11-05 2015-08-27 Ct De Ingeniería Genética Y Biotecnología Antígenos vacunales quiméricos contra el virus de la hepatitis c

Also Published As

Publication number Publication date
US10300131B2 (en) 2019-05-28
CA2986342A1 (en) 2017-01-12
US20230310590A1 (en) 2023-10-05
US20190224308A1 (en) 2019-07-25
EP3319997A4 (en) 2019-01-23
CA2986342C (en) 2024-04-02
US20180169219A1 (en) 2018-06-21
EP3319997A1 (en) 2018-05-16
US10881727B2 (en) 2021-01-05
WO2017006182A1 (en) 2017-01-12
US11576967B2 (en) 2023-02-14
US20210100895A1 (en) 2021-04-08

Similar Documents

Publication Publication Date Title
HK1255502A1 (zh) B型肝炎病毒(hbv)irna組合物及其使用方法
IL257384A (en) Preparations containing rnai and their use for the treatment of infection with the hepatitis b virus
HK1247238B (zh) 改造的crispr-cas9組合物和使用方法
IL258697A (en) Methods related to crispr/cas and compositions for the treatment of viral hepatitis b
IL244431A0 (en) Pharmacy methods and preparations for the treatment of hepatitis b virus infection
HK1250136A1 (zh) 具有改善的穩定性和免疫原性之疫苗組合物
IL259894A (en) Improved compositions and improved methods for viral delivery of neoepitopes and their use
HK1250480A1 (zh) 用於治療hbv感染的組合物和方法
HK1231402A1 (zh) 治療 型肝炎和 型肝炎病毒感染的方法
IL240227A0 (en) Immunogenic compositions containing viruses treated with silicates and methods of use
HK1255379A1 (zh) 丙型肝炎病毒免疫原性組合物及其使用方法
HK1254960A1 (zh) 冷沉澱物組合物及其製備方法
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法
HK1249046A1 (zh) 治療b型肝炎病毒的方法
LT3137078T (lt) Virusinio hepatito delta infekcijos gydymas
SG11201510266SA (en) Dengue virus vaccine compositions and methods of use thereof
SG11201704942QA (en) Dengue virus vaccine compositions and methods of use thereof
EP3515483A4 (en) HEPATITIS C VIRUS IMMUNOGENIC COMPOSITIONS AND THEIR USE PROCEDURES
EP3420076C0 (en) METHOD FOR THE PRODUCTION AND CHARACTERIZATION OF A VIRAL VACCINE AND A VIRAL VACCINE COMPOSITION